Oncoinvent Presents Final Safety and Efficacy Results from the Phase 1/2a Trial of Radspherin® to Treat Colorectal Cancer at the 15th PSOGI International Congress on Peritoneal Surface Malignancies

Oslo, Norway, 29 October 2025

Oncoinvent ASA, a clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, today announced the presentation of the previously reported final 18-months safety and efficacy results from its Phase 1/2a clinical trial (RAD-18-002) evaluating Radspherin® in patients with peritoneal metastases from colorectal cancer at the 15th PSOGI International Congress on Peritoneal Surface Malignancies, to be held at the Fira Barcelona October 29-31, 2025. Radspherin®, direct intraperitoneal targeting with the alpha-emitter radium-224, aims to eliminate post-surgery micro-metastases and thereby prevent or delay peritoneal recurrence.

In this Phase 1/2a trial, 36 out of 47 patients received the highest and recommended intraperitoneal dose of 7 MBq Radspherin® after dose escalation (1, 2, 4 and 7 MBq). The final 18-month data reported that only 10 of these 36 patients (27.8 %) had peritoneal recurrence. Remarkably, only 2 out of the 36 patients experienced peritoneal metastases as the only site of disease recurrence. Further, at 18 months 61.1% (22 of 36) patients had experienced new metastases overall, giving a median disease-free survival of 13.5 months.

“We are delighted to have the opportunity to present these encouraging data at such a highly specialized conference dedicated to peritoneal surface malignancies,” said Øystein Soug, CEO of Oncoinvent. “The theme of this year’s PSOGI conference — *‘From small beginnings to global force’* — perfectly reflects our ambitions for the development of Radspherin®.”

The results strengthen the potential for Radspherin® as a novel treatment option for patients with peritoneal metastases from colorectal cancer, demonstrating both clinical promise, as well as being well tolerated and safe to use, concludes the presenting author Dr. Stein Gunnar Larsen, Principal Investigator from the Norwegian Radium Hospital, Oslo University Hospital in Norway in the presented abstract.

About RAD-18-002

RAD-18-002 was an open label Phase 1/2a trial conducted in patients with peritoneal metastases from colorectal cancer. The trial was designed to evaluate dosing, safety and tolerability, and signal of efficacy of intraperitoneally administered Radspherin® following complete surgical resection and hyperthermic intraperitoneal chemotherapy (HIPEC). A total of 47 patients were enrolled across sites in Norway and Sweden.

About Oncoinvent

Oncoinvent is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. The lead product candidate, Radspherin®, uses the alpha-emitting radionuclide radium-224, directly targeting micro-metastases post-surgery, harnessing the benefits of modern radiopharmaceuticals without the complexities of biological targeting. Oncoinvent is investigating the safety and efficacy of Radspherin® in a clinical development program in two indications. One Phase 1 trial and one Phase 1/2a trial have been completed and one randomized Phase 2 trial is currently ongoing in the US and Europe. Early clinical efficacy data are highly encouraging, and no serious toxicity or safety concerns have been reported to date. The Oncoinvent team consists of approx. 40 employees and runs a state-of-the-art manufacturing facility to produce drug products for clinical trials in Nydalen, Oslo. Oncoinvent is listed on the Euronext Growth Oslo.

About Radspherin

Radspherin® is an investigational radiopharmaceutical designed for the local treatment of cancer that has spread to body cavities. It consists of billions of calcium carbonate microparticles containing the radioactive material radium-224. The mode of action is the decay of radium-224 emitting alpha-particles, a highly potent form of ionizing radiation. Radspherin® is investigated in clinical studies to treat peritoneal carcinomatoses from ovarian and colorectal cancer and it is administered intraperitoneally after surgical resection with removal of all macroscopic tumors.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Oncoinvent's plans, estimates, or expectations will be achieved. These forward-looking statements represent Oncoinvent's expectations as of the date of this press release, and Oncoinvent disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers.

For further information, please contact:
Oystein Soug, Chief Executive Officer
Email: soug@oncoinvent.com

Tore Kvam, Chief Financial Officer
Email: kvam@oncoinvent.com